ESMO 2024 – MediLink impresses in small-cell lung cancer
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.